Skip Nav Destination
Issues
1 April 2012
-
Cover Image
Cover Image
Ulmert and colleagues developed 89Zr–5A10, a radiolabeled monoclonal antibody that targets tumor-associated “free” prostate-specific antigen (PSA). The 89Zr–5A10 radiotracer selectively and noninvasively detected and visualized prostate cancer xenografts and bone lesions, and could quantitatively measure changes in PSA production in response to antiandrogen therapy. These findings have implications for the clinical assessment of advanced prostate cancer and the evaluation of experimental therapies. For details, please see the article by Ulmert and colleagues on page 320. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
In This Issue
In the Spotlight
Review
Research Briefs
Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
David Ulmert; Michael J. Evans; Jason P. Holland; Samuel L. Rice; John Wongvipat; Kim Pettersson; Per-Anders Abrahamsson; Peter T. Scardino; Steven M. Larson; Hans Lilja; Jason S. Lewis; Charles L. Sawyers
Research Articles
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Nicolai J. Birkbak; Zhigang C. Wang; Ji-Young Kim; Aron C. Eklund; Qiyuan Li; Ruiyang Tian; Christian Bowman-Colin; Yang Li; April Greene-Colozzi; J. Dirk Iglehart; Nadine Tung; Paula D. Ryan; Judy E. Garber; Daniel P. Silver; Zoltan Szallasi; Andrea L. Richardson
News in Brief
News in Depth
Research Watch
Breast Cancer
Drug Resistance
Leukemia
Lymphoma
Metastasis
Ovarian Cancer
Prostate Cancer
Sarcoma
Stem Cells
Tumor Suppressors
Tumorigenesis
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.